ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study (CHAPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00994630
Recruitment Status : Suspended (fail to get funding)
First Posted : October 14, 2009
Last Update Posted : August 16, 2011
Sponsor:
Information provided by:
University of Sao Paulo

Brief Summary:

The purpose of this study is to determine expression of chaperones proteins from the endoplasmatic reticulum stress response system in bipolar I patients (manic phase) compared to healthy controls.

Hypothesis: There is no difference in chaperones proteins expression between bipolar I manic patients and healthy controls


Condition or disease
Bipolar Disease Type I

Study Type : Observational
Estimated Enrollment : 20 participants
Time Perspective: Prospective
Official Title: Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study
Study Start Date : January 2010
Estimated Primary Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder
U.S. FDA Resources

Group/Cohort
BP I patients manic phase



Biospecimen Retention:   Samples With DNA
Dna and Rna analysis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Bipolar Disease type I manic phase
Criteria

Inclusion Criteria:

  • Bipolar Disease type I manic phase
  • YMRS > 14
  • HDRS < 9

Exclusion Criteria:

  • Use of lithium, divalproate, or carbamazepine in therapeutic levels over the past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994630


Locations
Brazil
Mood Disorders Program, Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo
Sao paulo, Brazil
Sponsors and Collaborators
University of Sao Paulo
Investigators
Principal Investigator: Ricardo A Moreno, MD, PhD Mood Disorders Program, Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Brazil
Study Director: Marcio G Soeiro de Souza, MD Mood Disorders Program, Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Brazil

Responsible Party: Ricardo Alberto Moreno, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT00994630     History of Changes
Other Study ID Numbers: CHAPS STUDY
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: August 16, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders